Opportunities of Interferon Therapy in Pregnant Women with Cervical Intraepithelial Neoplasia
Full Text (PDF)
Nina V. Zarochentseva 1 * , Julia M. Belaiya 2, Lela K. Dzhidzhikhiya 3, Valentina V. Malinovskaya 4
More Detail
1 Doctor of Sciences in Medicine, Professor of the Russian Academy of Sciences, Deputy Director for Scientific Work, Moscow Regional Research Institute of Obstetrics and Gynecology, Moscow, RUSSIA2 Candidate of Sciences in Medicine, Researcher, Polyclinic Department, Moscow Regional Research Institute of Obstetrics and Gynecology, Moscow, RUSSIA3 Candidate of Sciences in Medicine, Senior Researcher, Moscow Regional Research Institute of Obstetrics and Gynecology, Moscow, RUSSIA4 Doctor of Sciences in Biology, Professor, Head of the Laboratory, Laboratory of Ontogenesis and Correction of the Interferon System, National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation, Moscow, RUSSIA* Corresponding Author

Abstract

Objective: Due to hormonal and immune response changes, pregnancy contributes to their adverse stimulating effect on the progress of already existing hyperplastic processes in the cervix. The resulting aggravation of severity in their clinical course and intensity of the pathological process relatively frequently leads to precancerous conditions and cervical cancer developing further on. Some authors note the upward trend in the number of pregnant women having been diagnosed with pre-cancer and cancer of the cervix, as women postpone their maternity decisions increasingly more often. Currently, the tactics of managing pregnant women with cervical dysplasia consists in dynamic observation, including cytological study, colposcopic assessment of the state of surface cervical epithelium taking into account physiological particularities which are characteristic of pregnancy. The use of interferon therapy in pregnant female patients with HPV-associated cervical neoplasia is also expedient owing to its positive effect for reducing the CIN progression frequency, the probability of infecting the fetus with human papillomavirus, and the frequency of perinatal complications.
Methods: The study involved pregnant women in their second and third trimesters of gestation who have been diagnosed with cervical neoplasia (L-SIL, H-SIL). In comparison groups, behavior of cervical neoplasia was monitored against the background of the therapy conducted with interferon alpha-2b or without treatment.
Results: Against the background of the therapy conducted with interferon alpha-2b drug, higher frequency of the pathological process improving and lower frequency of its progressing into more severe dysplasia forms have been registered in the pregnant women with HPV-associated cervical neoplasia. However, it must be noted that efficiency of the treatment is higher in the group of pregnant women with L-SIL than in the H-SIL female patients.
Conclusion: In managing the CIN pregnant women, it is expedient to prescribe interferon therapy systemically and topically in the form of gel (Viferon®) which allows reducing inflammation, viral load, ensuring regression of L-SIL and stabilization of H-SIL.

Keywords

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Original Article

ELECTRON J GEN MED, Volume 18, Issue 5, October 2021, Article No: em314

https://doi.org/10.29333/ejgm/11124

Publication date: 04 Aug 2021

Article Views: 1515

Article Downloads: 1379

Open Access References How to cite this article